• Regions
  • Sector

Video & Audio

    •   The S&P Pharma Dose – Episode 16: Four Takeaways – Amgen Inc.

      S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt financed acquisitions/share repurchases.

    •   The S&P Pharma Dose – Episode 17: Pharma Outlook in 7 Minutes

      S&P Global Ratings credit analyst Arthur Wong attempts to share S&P’s current thoughts on the ratings outlook for pharmaceuticals in seven minutes or less, given looming U.S. corporate tax reform, continued industry M&A, and challenges faced by the generics and specialty pharma subsectors.

    •   Potential Downgrades Continue To Downward Trend

      Dropping for the sixth consecutive month, after having peaked at 737 in June 2016, the number of potential downgrades now stands at 636, as of May 26. In this CreditMatters TV segment, Gregg Moskowitz, Associate Director of Global Fixed Income Research, discusses this count, which has declined by 12 since April with 40 additions and 52 removals.

    •   Potential Upgrades See A Slight Uptick

      The number of potential bond upgrades slightly increased to 297 as of May 26, 2017, from 296 as of April 28, 2017. In this CreditMatters TV segment, Gregg Moskowitz, Associate Director of Global Fixed Income Research, discusses this rise, with most new additions coming from the utilities and media and entertainment sectors with eight each.

    •   Latin America Monday Morning Roundup – June 12, 2017

      Covering noteworthy research produced by S&P Global Ratings analysts in the region, "Latin America Monday Morning RoundUp" provides investors with a quick credit overview to start their week. Senior Director Jose Coballasi hosts this weekly segment of CreditMatters TV.

    •   NAFTA Renegotiations: Public Finance Credit Considerations

      In this CreditMatters TV segment, Associate Oscar Padilla and Senior Director Daniela Brandazza discuss the potential credit implications from a public finance perspective of the NAFTA renegotiation as it relates to credit quality on both sides of the border and ratings’ impact.